Project Grant F32AI183804
- This Project Grant award of $240,750.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research at the Children's Hospital Medical Center in Cincinnati, Ohio to study the contribution of adipose tissue immune cells to influenza pathogenesis. The research aims to better understand the critical processes that govern increased influenza severity in obesity, focusing on the role of immune...
- This $107,010 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research into the impact of diet-induced obesity on immune responses to enteric viral infections, specifically norovirus. The principal investigator's preliminary data indicates that mice fed a high-fat diet prior to norovirus infection clear the infection faster than control mice, suggesting obesity may enhance...
- This $2,190,435 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate obesity-driven alterations in B cell immunity. The primary objectives are to: Characterize the expansion of inflammatory TBET+CD11C+ B cells and associated T follicular/peripheral helper cells in the spleen, liver, and adipose tissue of obese mice, and examine the role of the...
- This $851,294 Project Grant was awarded on June 20, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Health Science Center at San Antonio. The grant supports research to "Dissect the Mechanism of Altered Immune Responses During Obesity". The key objectives are to investigate how obesity induces expansion of an inflammatory B cell subset, TBET+ CD11C+ B cells,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $704,041 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of California at Riverside. The grant supports research to investigate sex-dependent innate immune mechanisms that regulate type 2 immunity and obesity. The research aims to study macrophage-eosinophil interactions and the role of the RELMA protein in protecting against diet-induced obesity and...
- This Project Grant award of $239,120 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research by Tufts University School of Medicine to analyze the heterogeneity of cell death responses in influenza virus-infected cells. The objective is to elucidate the interplay between transcriptional and cell death responses to understand which cell death events can be safely targeted therapeutically...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $433,125 to The Ohio State University (OSU) to investigate the role of the influenza virus PB1-F2 protein in causing hypoxemia and acute respiratory distress syndrome (ARDS) in influenza infection. The research aims to understand how PB1-F2 interacts with mitochondrial proteins in alveolar type II (ATII) cells,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $148,880 Project Grant to St. Jude Children's Research Hospital Inc. under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant aims to uncover defects in the cellular and genetic machinery of germinal center reactions that impair the ability of obese individuals to sustain long-term B cell responses to the influenza A virus vaccine. The research will phenotypically profile...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $318,085 to support research on the role of antibodies in controlling virus infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The research aims to elucidate the...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the detrimental effects of the B-cell-Th17 axis on antiviral immunity in smokers. The $799,998 award to Baylor College of Medicine aims to determine the mechanism by which cigarette smoking impairs the development of long-term protective flu-specific B cell immunity. The research will focus on...
IMPACT OF OBESITY ON ANTIVIRAL NK CELL FUNCTION AND IMMUNE CROSSTALK WITH RESPIRATORY EPITHELIAL CELLS DURING INFLUENZA VIRUS INFECTION - RESEARCH SUMMARY RESPIRATORY INFECTIONS, INCLUDING THOSE CAUSED BY INFLUENZA A VIRUS (IAV), SIGNIFICANTLY CONTRIBUTE TO WORLDWIDE MORTALITY AND MORBIDITY. VULNERABLE POPULATIONS, SUCH AS INDIVIDUALS WITH OBESITY, HAVE BEEN FOUND TO HAVE INCREASED SUSCEPTIBILITY TO RESPIRATORY INFECTIONS. THE PREVALENCE OF OBESITY, DEFINED AS A BODY MASS INDEX (BMI) GREATER THAN 30, HAS BEEN STEADILY INCREASING OVER THE PAST DECADES. OBESITY IS KNOWN TO BE ASSOCIATED WITH ELEVATED INFLAMMATION AND DYSREGULATED IMMUNITY, BUT THE SPECIFIC MECHANISMS THROUGH WHICH INNATE IMMUNITY CONTRIBUTES TO THE INCREASED RISK OF INFECTION REMAIN UNKNOWN. NATURAL KILLER (NK) CELLS ARE CRITICAL TO THE INNATE IMMUNE RESPONSE AGAINST VIRAL INFECTIONS, INCLUDING IAV. NK CELLS PLAY A CRUCIAL ROLE IN EARLY VIRAL CLEARANCE BY DETECTING AND ELIMINATING VIRAL-INFECTED RESPIRATORY EPITHELIAL CELLS (RECS) AND PRODUCING ANTIVIRAL IFN- CYTOKINES. PREVIOUS STUDIES HAVE SHOWN THAT OBESITY CAN INTERFERE WITH NK CELL FUNCTION IN THE CONTEXT OF CANCER AND OTHER DISEASES. HOWEVER, THE IMPACT OF OBESITY ON NK CELL ANTIVIRAL RESPONSES, PARTICULARLY DURING IAV INFECTION, REMAINS TO BE INVESTIGATED. BASED ON THE EXISTING KNOWLEDGE GAPS, I HYPOTHESIZE THAT NK CELLS FROM OBESE INDIVIDUALS EXHIBIT BLUNTED FUNCTION DURING IAV INFECTION, LEADING TO A DISRUPTION IN NK CELL-EPITHELIAL CELL CROSSTALK. THIS DISRUPTION MAY CONTRIBUTE TO INCREASED SUSCEPTIBILITY AND SEVERITY OF INFECTION IN OBESE INDIVIDUALS. THE PRIMARY OBJECTIVE OF THIS RESEARCH IS TO IDENTIFY THE SPECIFIC CONTRIBUTION OF NK CELLS TO THE INCREASED SUSCEPTIBILITY AND DISEASE SEVERITY OBSERVED IN OBESITY. SPECIFIC AIM 1 WILL ASSESS THE IMPACT OF OBESITY ON NK CELL POPULATIONS AND FUNCTION IN RESPONSE TO IAV INFECTION IN BOTH SYSTEMIC AND MUCOSAL COMPARTMENTS. THIS WILL BE ACHIEVED BY COMPREHENSIVELY ANALYZING NK CELL PHENOTYPIC AND FUNCTIONAL CHARACTERISTICS USING ADVANCED FLOW CYTOMETRY AND TRANSCRIPTOMIC PROFILING OF NASAL WASH SAMPLES. SPECIFIC AIM 2 WILL INVESTIGATE THE CROSSTALK BETWEEN NK CELLS AND RECS DURING IAV INFECTION IN THE CONTEXT OF OBESITY. THE GOAL IS TO DETERMINE IF NK CELL DYSFUNCTION AND EPITHELIAL CELL SUSCEPTIBILITY TO INFECTION CONTRIBUTE TO INCREASED VIRAL REPLICATION AND DECREASED NK CELL CYTOTOXICITY. ADDITIONALLY, THE POTENTIAL THERAPEUTIC EFFECT OF METFORMIN, A DRUG COMMONLY USED FOR DIABETES AND WEIGHT LOSS, ON REVERSING THE IMPAIRMENT OF NK-EPITHELIAL CELL CROSSTALK IN OBESITY WILL BE EVALUATED. BY EMPLOYING A MULTIDISCIPLINARY APPROACH INVOLVING ADVANCED TECHNIQUES SUCH AS RNA TRANSCRIPTOMICS, COMPLEX FLOW CYTOMETRY, AND PRIMARY CELL COCULTURE SYSTEMS, I WILL ENHANCE MY UNDERSTANDING OF NK CELL ANTIVIRAL RESPONSES IN THE CONTEXT OF OBESITY. THE FINDINGS FROM THESE STUDIES WILL CONTRIBUTE TO OUR UNDERSTANDING OF HOW OBESITY AFFECTS INNATE IMMUNE RESPONSES IN HIGH-RISK POPULATIONS AND THEIR SUSCEPTIBILITY TO RESPIRATORY INFECTIONS. THE COLLABORATIVE ENVIRONMENT AND RESOURCES AT ST. JUDE PROVIDE AN IDEAL SETTING FOR CONDUCTING THIS RESEARCH AND FACILITATING THE RESEARCHER'S CAREER DEVELOPMENT IN MUCOSAL IMMUNITY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $78.0k | 8/25/25 | ||
| Not listed | $4.8k | 5/7/24 | ||
| Not listed | $0 | 5/7/24 | ||
| Not listed | $4.8k | 5/7/24 | ||
| Not listed | $69.5k | 3/6/24 |